Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.
Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The study will investigate the safety and effectiveness of daily post surgical scar
management, using a moisture-balancing base product containing different amounts of a novel
(NCE) antifibrogenic compound FS2, a natural metabolite of the kynurenine pathway. Results of
recent peer-reviewed, pre-clinical evidence warrant further investigation to validate
therapeutic scar preventive efficacy of topically administered/delivered FS2. There are no
known safety concerns with current product formulations. Recent Phase I clinical safety and
tolerability data further support continuation of the research proposed in this study.